Innoviva Forms Nortiva Bio for Oral Drug Innovation
Money

Innoviva Forms Nortiva Bio for Oral Drug Innovation

authorBy T. Harv Eker
DateJun 25, 2026
Read Time3 min
Innoviva, Inc. has announced a major strategic move with the establishment of Nortiva Bio, a new entity dedicated to advancing long-acting oral drug platforms. This initiative marks a significant step in pharmaceutical innovation, promising to revolutionize patient care through enhanced drug delivery mechanisms.

Innovating Treatment: Pioneering Extended-Release Oral Medications

Innoviva's Strategic Move: Introducing Nortiva Bio

Innoviva, Inc. (INVA) has unveiled its latest venture, Nortiva Bio, a biopharmaceutical company poised to transform the landscape of drug delivery. This new subsidiary will focus on developing extended-release oral treatments, leveraging cutting-edge technology to improve patient compliance and therapeutic outcomes.

The LYNX Platform: A Game-Changer in Drug Delivery

At the heart of Nortiva Bio's mission is the proprietary LYNX drug delivery platform. This innovative technology is designed to convert conventional daily oral medications into treatments with prolonged efficacy, potentially enabling dosing intervals of up to one month. Such advancements aim to significantly enhance treatment effectiveness, safety profiles, medication adherence, and overall patient experience across diverse therapeutic domains.

Nortiva's Genesis: From Acquisition to Innovation

Nortiva Bio's formation is a direct result of Innoviva's strategic acquisition of the LYNX platform from Lyndra Therapeutics in 2025. Operating as a wholly-owned subsidiary, Nortiva is now set to capitalize on this advanced technology, ushering in a new era of convenient and effective long-acting oral therapies.

Expanding Global Reach: XACDURO Distribution Agreement

In a related development, Innoviva Specialty Therapeutics, another subsidiary of INVA, recently forged an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories. This partnership pertains to XACDURO, an important medication, and covers its development, regulatory approval, and commercialization in key international markets, including South and Central America, the Caribbean, Russia, and the Commonwealth of Independent States countries.

Innoviva's Sustained Rights and Financial Benefits

Under the terms of the agreement, Innoviva Specialty Therapeutics will retain the rights to XACDURO in markets not covered by the licensing deal. Furthermore, Innoviva stands to receive upfront payments, milestone-based payments contingent on regulatory and commercial achievements, and royalties from sales generated within the stipulated territories, bolstering its financial position and incentivizing further innovation.

Innoviva's Core Focus: Critical Care and Infectious Diseases

Innoviva, Inc. positions itself as a biopharmaceutical leader with a primary focus on critical care and infectious disease treatments. The company benefits from a stable revenue stream derived from its respiratory royalty portfolio, complemented by strategic investments in novel and impactful therapies, reinforcing its commitment to addressing unmet medical needs.

More Articles
Money
Micron's Stock Soars on Strong Earnings, AI Memory Demand
Micron's stock surged approximately 18% after reporting robust third-quarter earnings that surpassed analyst expectations. The memory giant showcased record revenue, gross margin, and earnings per share, largely driven by insatiable demand for AI-specific memory. Strategic agreements with customers, including take-or-pay commitments totaling billions, highlight the critical role of memory in the burgeoning AI sector and signal a potential shift away from the industry's traditional cyclicality.
By Dave RamseyJun 25, 2026
Money
Fidelity National Information Services: A Potential Surge in Stock Value
Fidelity National Information Services (FIS) is gaining attention from analysts who predict a significant upside potential of 46% for its stock. Despite recent target price adjustments due to revised fiscal year forecasts, the company is innovating with new digital wealth solutions. This financial technology provider, based in Jacksonville, Florida, continues to be a key player in banking and capital markets solutions.
By Vicki RobinJun 24, 2026
Money
Wendy's Returns to Meme Stock Status Amidst Retail Investor Frenzy
Wendy's stock recently experienced a significant surge, reclaiming its meme stock title. This unexpected rally was fueled by a viral post on WallStreetBets, a subreddit known for igniting short squeezes. Despite struggling fundamentals, including an 8% drop in Q1 2026 same-restaurant sales and a 42% decrease in net income, retail investors aggressively bought shares. The appointment of a new CFO with a successful past tenure at Potbelly also contributed to the bullish sentiment, leading to a more than 30% increase in share price by midday Wednesday.
By T. Harv EkerJun 24, 2026
Money
Uber's European Robotaxi Expansion: A Strategic Move Amidst Market Fluctuations
Uber Technologies is poised to launch its first commercial robotaxi pilot in Madrid, Spain, in partnership with WeRide. This expansion, part of a larger agreement spanning 15 cities by 2030, comes as analysts maintain a positive outlook on Uber despite a lowered price target, recognizing its potential in the evolving ride-hailing market driven by autonomous vehicles.
By Mr. Money MustacheJun 24, 2026
Money
Wise Group's Promising Future Despite Market Fluctuations
Despite recent stock market struggles, analysts remain optimistic about Wise Group PLC's long-term prospects. Berenberg Bank and Jefferies have reiterated 'Buy' ratings, with revised price targets indicating significant upside potential. The company's robust business model, expanding customer base, and successful Wise Platforms initiatives underscore its inherent strength and growth trajectory, separating short-term market volatility from fundamental performance.
By Ramit SethiJun 24, 2026